Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease

Introduction Infliximab (IFX) is very effective in active inflammatory bowel disease (IBD) but up to nearly 50 %l of patients will lose response or experience attenuated response to IFX due to fluctuating drug levels or formation of antibodies to IFX (ATI). Patients were allocated to three groups based on the intent of TDM: maintenance group (MG) - proactive TDM on patients with quiescent IBD, secondary loss of response group (SG) -reactive TDM on active patients with established primary response to IFX, and post-induction group (PG) - TDM at week 14 post-induction. References 1 Ding NS, Hart A, De Cruz P. Systematic review: predicting and optimising response to anti-TNF in Crohn's disease - algorithm for practical management.